




This open-access article is distributed under the terms of the Creative Commons Attribution Non Commercial 4.0 License (CC BY-NC 4.0). 
 
 
Cost-Effectiveness of Sorafenib for Metastatic Renal Cell Carcinoma: 
A Systematic Review 
Mohammad Hossein Motevalli, Saeed Taheri, Farzad Peiravian, Nazila Yousefi* 
 





Received: August 2019 
Accepted: December 2019 











Introduction: Sorafenib is a multi-kinase inhibitor and decreases tumor cell 
proliferation. This study aimed to systematically review the existing evidence related to 
its cost-effectiveness.  
Methods and Results: EMBASE, MEDLINE, PUBMED, Google Scholar, and the 
Scopus database were searched and articles were selected on the basis of their correlation 
with the economic evaluations of Sorafenib. The quality of the selected studies was 
assessed using the Quality of Health Economic Studies instrument. This review revealed 
costs per quality-adjusted life years in the range of US $89,160 to $118,825, depending 
on whether the setting was first-line or second-line and which comparator is utilized. 
The results indicated that Sorafenib had not been considered as an appropriate treatment 
option for patients with metastasis Renal Cell Carcinoma (mRCC). Sorafenib was 
dominated (i.e. higher cost and lower efficacy) in comparison with Sunitinib in all cases. 
However, Sorafenib would be more cost-effective in comparison with bevacizumab plus 
interferon alfa in the treatment of mRCC. 
Conclusion: Sorafenib was more effective with higher cost than Best Supportive Care 
but Sorafenib was not cost-effective in view of current willingness to pay threshold. 
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Renal cell carcinoma (RCC), which originates from or 
rooted within the renal cortex, constitutes 80 to 85 
percent of primary renal neoplasms. Diagnosis median 
age is considered 65 years with a variable incidence over 
the world [1,2]; nearly 84000 cases of RCC and 35000 
death cases resulting from kidney cancer were reported 
in the European Union in 2012 [3]. 
Nowadays, patients suffering from kidney cancer have 
better chances of 5-year survival compared to 50 years 
ago, increasing from 5-year survival rate of 34% in 1954 
to 62% in 1996 and, then, to 73% from 2005 to 2011 
[4,5]. However, fewer than 10% of patients with 
metastatic RCC (mRCC) had 5-year survival chances 
[6]. Unfortunately, RCC has a poor prognosis in a 
significant proportion of patients [7]. 25-30% of RCC 
patients have metastasis causing the majority of deaths 
related to RCC [8]. The evaluated economic burden of 
mRCC was about US $107-556 million in the US in 
2006 [9]. 
Although, mRCC does not respond well to treatment, in 
terms of efficacy and safety, Sorafenib (SFN) fares 
better than other treatment strategies including surgery 
and systemic chemotherapy [9], in general. SFN is a 
multi-kinase inhibitor, which was approved for RCC in 
2005 and decreases tumor cell proliferation. It is 
administrated 400mg orally twice a day. However, 
according to recent studies, dose-adjusted SFN regimen 
results in better efficacy-safety balance [10]. 
There are several approved treatments for RCC such as 
surgical interventions, Sunitinib (SUN), Everolimus, 
Axitinib, Bevacizumab (BVC), and Lenvatinib. In light of 
the ever-increasing costs of the healthcare system and a 
great expense of the newly introduced treatments, it has 
become more crucial than ever to choose more cost-
effective treatments among different alternatives. Cost-
effectiveness studies may provide healthcare decision-
makers with the requisite insights to make informed 
choices. 
Hence, this study was aimed to systematically review the 
economic evaluations of SFN in the treatment of RCC to 
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assist decision-makers to maintain costs and ensure access 
to effective treatments within limited healthcare budgets. 
2. Methods 
A systematic literature search in EMBASE, MEDLINE, 
PUBMED, Google Scholar, and the Scopus database 
was conducted between November 2004 and April 2018. 
The following key words were used in our search strategy: 
“Sorafenib”, “renal”, “kidney”, “cancer”, “carcinoma”, 
“economic evaluation”, “pharmacoeconomic evaluation”, 
“cost-effectiveness”, “cost-utility”, “cost-benefit”, and 
“cost-minimization”. These keywords were limited to 
titles and abstracts.  
2.1. Inclusion or exclusion criteria:  
The search was limited to articles published in English. 
In addition, studies without a full text were left out. The 
studies included in our corpus also had to meet the 
following inclusion criteria:  
 Dealing with adults suffering from metastatic or 
advanced renal cell carcinoma as patient population. 
 Taking both cost and clinical consequences into 
account. 
 Representing the SFN-containing therapy as one of 
the treatment arms. 
The search strategy identified 254 articles and 5 studies'  
were selected based on their eligibility (Fig. 1). 
2.2. Quality assessment  
To evaluate the quality of the included studies, the 
Quality of Health Economic Studies (QHES) instrument, 
which is shown in table 1, was used. QHES score shows 
 
 the quality of economic studies as follows: poor (QHES 
score<50), fair (QHES score ≥ 50 and <75), and good 
(QHES score≥75 and ≤100). 
 
 
Figure 1. PRISMA diagram 
Table 1. The Quality of Health Economics Studies (QHES) instrument 
 Questions Points 
1 Was the study's objective presented in a clear, specific, and measurable manner? 7 
2 Were the perspectives of the analysis (societal, third-party payer, etc.) and reasons for their selection stated? 4 
3 
Were variable estimates used in the analysis from the best available sources (i.e., randomized control trial - best, expert opinion - 
worst)? 
8 
4 If estimates came from a subgroup analysis, were the groups pre-specified at the beginning of the study? 1 
5 
Was uncertainty handled by (1) statistical analysis to address random events, (2) sensitivity analysis to cover a range of 
assumptions? 
9 
6 Was incremental analysis performed between alternatives for resources and costs? 6 
7 Was the methodology for data abstraction (including the value of health states and other benefits) stated? 5 
8 
Did the analytic horizon allow time for all relevant and important outcomes? Were benefits and costs that went beyond 1 year 
discounted (3% to 5%) and justification given for the discount rate? 
7 
9 Was the measurement of costs appropriate and the methodology for the estimation of quantities and unit costs clearly described? 8 
10 
Were the primary outcome measure(s) for the economic evaluation clearly stated and did they include the major short-term, long-
term, and negative outcomes? 
6 
11 
Were the health outcomes measures/scales valid and reliable? If previously tested valid and reliable measures were not available, 
was justification given for the measures/scales used? 
7 
12 
Were the economic model (including structure), study methods and analysis, and the components of the numerator and denominator 
displayed in a clear and transparent manner? 
8 
13 Were the choice of economic model, main assumptions, and limitations of the study stated and justified? 7 
14 Did the author(s) explicitly discuss the direction and magnitude of potential biases? 6 
15 Were the conclusions/recommendations of the study justified and based on the study results? 8 
16 Was there a statement disclosing the source of funding for the study? 3 
Total Points 100 
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Five articles were identified in the PubMed database 
meeting the inclusion/exclusion criteria (Table 2). Two 
of them compared SUN with SFN and BVC plus 
interferon-α (BVC/IFN), one compared SFN versus 
Everolimus, and the other two compared SFN versus 
best supportive care (BSC). No more full-text study was 
detected in Google search engine. However, seven more 
abstracts were recorded. Although overall 12 studies 
dealt with some kind of cost analysis, only nine studies 
reported information on cost-effectiveness. 
The Cost-effectiveness analyses of the SFN-
containing therapy were conducted in four different 
countries including USA (n = 2), Spain (n = 1), Cyprus 
(n=1), and UK (n=1). Most of them were performed in a 
single country. Almost all studies adopted a healthcare 
system’s or a payer’s or third-party payer’s perspective. 
Markov model was applied in all of the studies in a  
6-year to life-time time horizon. A discount rate of 3% 
or 3.5% was used in the studies and all studies disclosed 
their source of funding. 
All the included studies were published in medical 
journals implementing limited follow up time data in 
their models. Accordingly, all of them were considered 
medium level of evidences. The primary focus of the 
studies was comparing SFN, SUN, Everolimus, or BSC 
in the treatment of mRCC in terms of cost-effectiveness. 
Three studies had been sponsored by Pfizer, Bayer, and 
the UK National Health System. One study denied 
receiving any financial support (table 2). Cost-
effectiveness results of SFN in metastatic renal cell 
carcinoma were shown on table 3. 
 
Table 2. Characteristics of articles assessing cost-effectiveness of SFN in metastatic renal cell carcinoma 
Study 
(year) 








Aller et al.  
(2011) 
Spain Third- party payer Euro/2008 Markov 10 year 3% Pfizer 
Benedict et al. 
(2011) 
USA/Sweden Third- party payer Dollars/2007 Markov lifetime 3% Pfizer 
petrou et al. 
(2014) 
Cyprus Payer Euro/2012 Markov 10 year 3.5% No 
Casciano et al. 
(2011) 
USA US payer Dollar/2010 Markov 6 year 3% Novartis 
Hoyle et al. 
(2010) 
UK 
UK National Health 
Service 
Pound/2008 Markov 10 year 3.5% UK NHS Research 
 
 
Table 3. Cost-effectiveness results of SFN in metastatic renal cell carcinoma 
Study Population Comparator Type of cost included Cost Effectiveness ICER 
Casciano 




post discontinuation treatments, 
drugs, nurse care, adverse event(AE), 
general practitioner visits, CT scans, 




LY: 0.533  
vs 1.805  






SUN vs SFN 
and 
BVC/IFN 
drug treatment costs; specialist visits; 
hospitalizations; general practitioner 
and nurse visits; laboratory testing of 
blood counts, metabolic panels and 
thyroid function; chest and/or pelvis  






vs 2.90 vs 2.67 
QALY: 1.70  
vs 1.87  
vs 1.71 
SFN vs SUN:  dominated 
SFN vs BVC/IFN: cost-
effective* 
Benedict 
 et al. 
mRCC 
SUN vs SFN 
and 
BVC/IFN 
drugs, specialist visits, 
hospitalizations, general practitioner 
and nurse visits; laboratory testing of 
blood counts, metabolic panels and 
thyroid function; chest/pelvis CT 
scans, X-rays and MRI,AEs 




LY: 2.743  
vs 2.900  
vs 2.670 
QALY: 1.706 vs 
1.876  
vs 1.714 
SFN vs SUN: dominated 
SFN vs BVC/IFN: cost-
effective* 
Hoyle 
 et al. 
advanced 
RCC 
SFN VS BSC 
Drugs, medical management 
(computed tomography scans, 
monitoring, blood tests), AE, GP visit 
, nurse care 
£23,860 vs 
£3,797 









SFN VS BSC 
Drugs, hospitalization, GP visit, 
nurse care, AE, Specialist, CT 
€23780 vs €7330 
QALY: 0.639 vs 
0.478 
€102,059/QALY 
* less costly and less effective, but below the acceptable willingness to pay 
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3.1. Sorafenib versus best supportive care 
Hoyle et al. [11] developed a Markov cohort model to 
evaluate the cost-effectiveness of SFN versus BSC as a 
second-line treatment employing data from a random 
clinical trial (RCT) by Escudier et al. [12]. Costs were 
calculated in pounds in 2008 with a 10-year time horizon 
and a 3.5% discount rate. The resources used on medical 
costs were based on national tariffs, experts’ opinion, 
and published sources. The results illustrated that SFN 
was associated with the incremental effectiveness of 0.33 
life years gained (LYG) and 0.27 quality-adjusted life 
years (QALYs). As a result, the incremental cost-
effectiveness ratio (ICER) was estimated as £54,565 per 
LYG and £75,398 per QALY. Sensitivity analysis 
showed that the model was sensitive to effectiveness 
data for overall survival, health state utilities, and drug 
acquisition costs. Finally, the authors, who disclosed 
their employment in the UK NHS, concluded that 
although SFN was more effective than BSC, it was not 
cost-effective at the threshold of £30,000 [11].  
In a different study, Petrou et al. [2] compared SFN as a 
second-line therapy to BSC employing a Markov model. 
The model was run in a 10-year time horizon from the 
payer perspective. Two single-arm trials were used to 
extract SFN efficacy data. The results indicated an 
incremental QALY of 0.161 (0.639 versus 0.478 QALY) 
together with an incremental cost of €16,450 (€23,780 
versus €7,330) resulting in an ICER of €102059/QALY. 
In conclusion, the study mentioned the probability of 
SFN being cost-effective as 0% at the threshold of 
€60,000. The one-way sensitivity analysis illustrated that 
the result was sensitive to effectiveness (overall survival) 
and the price of products. As the authors noted, the most 
important limitation of their study was comparing SFN 
with BSC since some comparators such as Axitinib and 
Everolimus were available as second-line treatments. 
The study had not  been sponsored [2]. 
3.2. Sorafenib versus Everolimus 
Casciano et al. [13] compared the cost and effectiveness 
of SFN versus Everolimus in 2011 from a payer 
perspective in second-line setting after the failure of 
first-line SUN as well as in the second-line setting. A 
Markov cohort model was used with a discount rate of 
3% and a 6-year time horizon. An incremental cost per 
QALY of $89,160 and $64,185/LYG were calculated for 
SFN in treatment of advanced RCC in comparison with 
Everolimus. The sensitivity analysis showed that the 
model was sensitive to treatment effectiveness variations 
(hazard ratio for overall survival), drug price, and health 
state utilities. Finally, this study, which had been funded 
by Novartis Pharmaceutical Corporation, concluded that 
SFN was not cost effective at the threshold of $50,000 [13]. 
3.3. Sorafenib versus Sunitinib 
Benedict et al. [14] analyzed three new drugs as first-line 
treatments for mRCC including SUN, SFN, and 
BVC/IFN. A Markov model was utilized using a 3% 
discount rate from the third-party payer’s perspective. 
All the costs were measured in US dollars in 2007. 
Given a lifetime horizon, the study demonstrated that 
SFN would result in lower QALYs gained and higher 
costs than SUN (1.706 versus 1.876 QALYs and 
$381,922 versus $369,346, respectively). As a result, 
SFN was found as a dominated strategy. The sensitivity 
analysis illustrated that the model was sensitive to hazard 
ratio for overall survival, costs of BSC, the price of 
drugs, and utilities associated with treatments [14]. 
Similarly, Aller et al. [7] adopted a Markov cohort 
model to estimate the comparative cost-effectiveness of 
SFN, SUN, and BVC/IFN from the third-party payer's 
perspective. The overall survival (OS) and progress free 
survival (PFS) of SFN was derived from two different 
trials in metastatic renal cell carcinoma [15,16]. Costs 
were reported in Euros in 2008 in a 10-year time 
horizon. LYs and QALYs were calculated as 2.74 and 
1.7 for SFN and 2.9 and 1.87 for SUN, respectively. In 
addition, SFN was associated with an incremental cost of 
€1,124 compared to SUN (€119,541 versus €118,417). 
Finally, the results showed that SFN was the dominated 
alternative compared to SUN due to its higher cost and 
lower efficacy. The one-way sensitivity analysis showed 
that the result was sensitive to drug costs, utility values, 
and hazard ratio, for both OS and PFS[7]. 
3.4. Quality assessment (QHES) 
The results of the quality assessment using the QHES 
instrument have been presented in Table 4. 
 
Table 4. Quality assessment of studies using the QHES instrument 
Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Score 
Aller et al. √ √ x √ √ √ √ √ √ √ √ √ √ √ √ √ 92 
Benedict et al. √ ± √ √ √ √ √ √ √ √ √ √ √ √ √ √ 98 
Casciano et al. √ ± √ √ √ √ √ ± √ √ √ √ √ √ √ √ 94.5 
Hoyle et al. √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 100 
Petrou et al. √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 100 
Statement frequency 5 5 4 5 5 5 5 5 5 5 5 5 5 5 5 5 --- 
Systematic Review on Cost-Effectiveness of Sorafenib  5  
 This open-access article is distributed under the terms of the Creative Commons Attribution Non Commercial 4.0 License (CC BY-NC 4.0). 
 
It was found that the quality of the included studies was 
at a high level (Mean QHES Score: 96.9). The objectives 
of studies were clearly presented in all studies (Question 
1). The perspective of the analysis had been stated in all 
studies. However, two studies have not stated any 
justification for the reasons of selection (Question 2). 
The best available source of data was utilized by all the 
studies except Aller et al. [7] using expert opinion 
(Question 3). When subgroup analyses were conducted, 
the groups were pre-specified (Question 4) and all the 
studies handled uncertainty by both one-way sensitivity 
analysis as well as probabilistic sensitivity analysis 
(Question 5). All studies performed incremental analysis 
among alternatives for effectiveness and costs (Question 
6). In addition, all of the studies provided detailed 
information on the methods used to derive effectiveness 
(Question 7). Information on the discounting rate for 
costs or utilities had been stated in all of them. 
Regarding the time horizon, the study done by Casciano 
et al. [13] revealed that its shorter time horizon 
compared to other studies might not have covered for all 
relevant and important outcomes (Question 8). 
Moreover, all studies measured costs appropriately 
(Question 9).  
The primary outcome measures had been clearly stated 
in all studies and other relevant outcomes were 
addressed (Question 10). In addition, the reliability and 
validation of health outcome measures had been tested 
before (Question 11). The model had been clearly 
explicated by the authors of all studies (Question 12). 
Then, the justification for the choice of the model and 
discussion on results, assumptions, and limitations had 
been given by all the studies (Question 13). The 
direction and magnitude of potential bias had also been 
discussed by the authors of all studies (Question 14) and 
the conclusions drawn by the authors of all studies were 
based on the study results and sounded reasonable 
(Question 15). Finally, all of them disclosed their source 
of funding for their studies (Question. 16). 
4. Discussion and Conclusion 
This is the first systematic review of the economic 
evaluation studies of SFN in RCC treatment. The cost-
effectiveness of SFN has been evaluated in several 
distinct treatments? Therapy protocols (first- and second-
line) against various treatment regimens. The findings in 
this study point to an incremental cost per QALY in the 
range of $89,160 to $118,825, depending on whether the 
setting is first-line or second-line and which comparator 
is utilized.  
Overall, the results indicated that SFN had not been 
considered as a cost-effective treatment option for 
patients with mRCC. Briefly, SFN was dominated with a 
higher cost and lower efficacy than SUN in all cases 
[7,14]. However, compared to BVC/IFN, SFN was 
associated with lower cost as well as lower efficacy [14]. 
A closer look revealed that SFN would be more cost-
effective than BVC/IFN in  treating of mRCC. 
Compared to BSC, SFN was costlier and more effective 
in all the studies. However, SFN was not considered as a 
cost-effective strategy due to its high calculated ICERs 
(£75,398 and €102,059), which was beyond an 
acceptable range [2,11].  
All studies mentioned that the model was sensitive to 
clinical effectiveness (overall survival) and drug 
acquisition cost. In addition, some of them also showed 
sensitivity to health state utility [11,13]. Not only being 
sensitive to clinical effectiveness somewhat makes the 
result questionable, but also extrapolating clinical 
efficacy and treatment persistency from short-term RCTs 
to a long treatment period carries significant uncertainty 
and requires additional assumptions that are not well 
acknowledged in the literature. 
For transferability of the results of these studies, in 
addition to noting different health care settings, different 
costs, different medical procedures, etc., willingness to 
pay should also be consider an important contributing 
factor. It should also be noted that willingness to pay 
threshold is not a rigid cut-off all over the world. For 
example, in the United States, a threshold of $50,000 per 
QALY is generally accepted to assess the cost-
effectiveness of an intervention. Furthermore, health care 
authorities in Spain consider a treatment as a cost-
effective strategy if it results in an ICER of 
≤€50,000/QALY. In the UK, NICE advocated a cut-off 
at an ICER of £30,000 /QALY. So, the results should be 
interpreted with a view to or considering the specific 
willingness to pay threshold in different jurisdictions.  
Generalizability of the trials to the wider patient 
population is another limitation in targeted studies. Most 
of the patients included in the clinical trials have had 
good performance and prognosis, clear cell mRCC, and 
undergone a prior nephrectomy. Accordingly, the 
generalizability of estimated overall survival to the wider 
patient population can prove a limiting factor. In 
addition, the generalizability of cost-effectiveness 
studies, which have been conducted in a specific 
country, to other health care settings may be limited due 
to the differences in costs between different countries 
such as developed and developing countries. 
In sum, according to high quality published cost-
effectiveness studies, SFN has not been considered as a 
cost-effective treatment option for patients with mRCC. 
To be more specific, three main conclusions were drawn 
from this systematic review: 1. SFN is dominated in 
comparison with SUN, 2. SFN is more effective and 
costly in comparison with BSC but not cost-effective at 
acceptable ICER thresholds, and 3) SFN is less effective 
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